Hemagen Diagnostics, Inc. HMGN

HMGN Company Overview

Hemagen Diagnostics, Inc. (OTC: HMGN) was a U.S.-based medical diagnostics company focused on the development, manufacture, and commercialization of in vitro diagnostic products. The company primarily operated within the healthcare diagnostics and biotechnology sectors, with an emphasis on blood-testing technologies used for autoimmune and infectious disease detection. Its historical product portfolio included enzyme-linked immunosorbent assay (ELISA) and Western blot-based diagnostic kits used by clinical laboratories, hospitals, and reference testing facilities.

The company’s principal revenue drivers historically came from diagnostic test kit sales and related laboratory products. Hemagen was known for serving niche diagnostic markets, particularly in autoimmune disease testing and confirmatory infectious disease assays. Publicly available filings indicate the company experienced prolonged financial and operational challenges over time, and later disclosures reflected limited operating activity. Data regarding current active operations, product commercialization status, and ongoing market participation is inconclusive based on available public sources.